MRK US58933Y1055

Report

Delayed Nyse - 05/16 04:03:28 pm EDT
92.32	USD		+2.11%

10:49a	Neoleukin Therapeutics Treats First Tumor Patient in Trial Evaluating NL-201 With Keytruda	MT
10:44a	Athenex, Merck Collaborate to Study Oraxol Plus Keytruda in Non-Small Cell Lung Cancer	MT
02:10a	Rising Cyber Attacks Could Make Insurance Unaffordable	AQ

Calendar

Event chart MERCK & CO., INC.

Upcoming events on MERCK & CO., INC.

05/24/22 \| 09:00am		Annual General Meeting
07/28/22		Interim 2022 Earnings Release
07/28/22 \| 08:00am		Interim 2022 Earnings Call
10/27/22		Q3 2022 Earnings Release
10/27/22 \| 08:00am		Q3 2022 Earnings Call
02/02/23		FY 2022 Earnings Release (Projected)
05/02/23		Q1 2023 Earnings Release (Projected)
07/28/23		Interim 2023 Earnings Release (Projected)
10/26/23		Q3 2023 Earnings Release (Projected)

Past events on MERCK & CO., INC.

05/11/22 \| 11:40am		Bank of America Healthcare Conference
04/28/22 \| 08:00am		Q1 2022 Earnings Call
04/28/22 \| 06:30am		Q1 2022 Earnings Release
04/23/22		European clinical microbiology & infectious diseases congress - abstract number : 4545
04/23/22		European clinical microbiology & infectious diseases congress - abstract number : 4548
04/23/22		European clinical microbiology & infectious diseases congress - abstract number : 4514
04/23/22		European clinical microbiology & infectious diseases congress - abstract number : 4865
04/23/22		European clinical microbiology & infectious diseases congress - abstract number : 5113
04/05/22 \| 10:00am		Investor Meeting - Cardiovascular Event
03/14/22		Ex-dividend day for

Past dividends on MERCK & CO., INC.

03/14/22		Quarterly 0.69 USD
12/14/21		Quarterly 0.69 USD
09/14/21		Quarterly 0.65 USD
06/14/21		Quarterly 0.65 USD
06/03/21		0
03/12/21		Quarterly 0.65 USD
12/14/20		Quarterly 0.65 USD
09/14/20		Quarterly 0.61 USD
06/12/20		Quarterly 0.61 USD
03/13/20		Quarterly 0.61 USD

Annual results

Fiscal Period : December		2017	2018	2019	2020	2021	2022
Sales M $	Released Forecast Spread	40 122 40 205 -0,21%	42 294 42 234 0,14%	46 840 46 818 0,05%	47 994 48 177 -0,38%	48 704 48 367 0,70%	57 853
Operating income (EBITDA) M $	Released Forecast Spread	15 131 15 472 -2,2%	15 781 15 310 3,1%	19 572 18 761 4,3%	20 570 19 815 3,8%	20 910 19 760 5,8%	23 964
Operating profit (EBIT) M $	Released Forecast Spread	13 551 13 722 -1,2%	13 926 13 815 0,80%	15 920 16 276 -2,2%	16 945 17 366 -2,4%	17 696 17 554 0,81%	22 243
Pre-Tax Profit (EBT) M $	Released Forecast Spread	6 747 6 720 0,40%	8 701 8 296 4,9%	11 464 12 277 -6,6%	8 791 14 906 -41%	13 879 12 048 15%	19 102
Net income M $	Released Forecast Spread	2 568 5 147 -50%	6 220 6 462 -3,7%	9 843 9 957 -1,1%	7 067 12 094 -42%	13 049 11 797 11%	15 590
EPS $	Released Forecast Spread	0,93 1,85 -50%	2,32 2,44 -5,0%	3,81 3,83 -0,52%	2,78 4,71 -41%	5,14 4,70 9,4%	6,14
Announcement Date		02/02/2018	02/01/2019	02/05/2020	02/04/2021	02/03/2022	-

Quarterly results

Fiscal Period : December

2021 Q1

2021 Q2

2021 Q3

2021 Q4

2022 Q1

2022 Q2

Sales
M $

Released
Forecast
Spread

12 080
12 648
-4,5%

11 402
11 193
1,9%

13 154
12 320
6,8%

13 521
13 212
2,3%

15 901
14 648
8,6%

13 648

Operating income
(EBITDA)
M $

Released
Forecast
Spread

5 220
5 416
-3,6%

4 659
4 555
2,3%

6 111
5 175
18%

5 670
4 892
16%

5 918

4 960

Operating profit
(EBIT)
M $

Released
Forecast
Spread

4 290
4 844
-11%

3 969
4 032
-1,6%

5 352
4 708
14%

4 835
4 528
6,8%

6 448
5 393
20%

4 932

Pre-Tax Profit
(EBT)
M $

Released
Forecast
Spread

1 717
3 367
-49%

Net income
M $

Released
Forecast
Spread

3 179
3 712
-14%

1 214
2 805
-57%

4 567
3 078
48%

3 758
3 557
5,6%

4 310
3 768
14%

3 512

EPS
$

Released
Forecast
Spread

1,25
1,43
-13%

0,48
0,82
-41%

1,80
1,35
33%

1,48
1,35
9,8%

1,70
1,48
15%

1,39

Announcement Date

04/29/2021

07/29/2021

10/28/2021

02/03/2022

04/28/2022

Previous year

Next Year

Upcoming sector events for MERCK & CO., INC.

07/19/22 \| 06:25am		JOHNSON & JOHNSON : Interim 2022 Earnings Release
07/21/22		ROCHE HOLDING AG : Interim 2022 Earnings Release
07/29/22		ABBVIE INC. : Interim 2022 Earnings Release (Projected)
08/02/22		PFIZER INC. : Interim 2022 Earnings Release (Projected)
08/04/22 \| 06:25am		ELI LILLY AND COMPANY : Interim 2022 Earnings Release
10/18/22		ROCHE HOLDING AG : Q3 2022 Sales and Revenue Release
10/18/22		JOHNSON & JOHNSON : Q3 2022 Earnings Release
11/01/22		PFIZER INC. : Q3 2022 Earnings Release (Projected)
11/01/22 \| 05:25am		ELI LILLY AND COMPANY : Q3 2022 Earnings Release
11/04/22		ABBVIE INC. : Q3 2022 Earnings Release (Projected)

More events

Past sector events for MERCK & CO., INC.

05/03/22 \| 06:45am		PFIZER INC. : Q1 2022 Earnings Release
04/29/22 \| 07:43am		ABBVIE INC. : Q1 2022 Earnings Release
04/28/22 \| 06:25am		ELI LILLY AND COMPANY : Q1 2022 Earnings Release
04/25/22 \| 01:00am		ROCHE HOLDING AG : Q1 2022 Sales and Revenue Release
04/19/22 \| 06:25am		JOHNSON & JOHNSON : Q1 2022 Earnings Release
02/08/22 \| 06:45am		PFIZER INC. : FY 2021 Earnings Release
02/03/22 \| 06:25am		ELI LILLY AND COMPANY : FY 2021 Earnings Release
02/03/22 \| 01:00am		ROCHE HOLDING AG : FY 2021 Earnings Release
02/02/22 \| 07:43am		ABBVIE INC. : FY 2021 Earnings Release
01/25/22 \| 06:25am		JOHNSON & JOHNSON : FY 2021 Earnings Release

More events

Analysis

Merck sees up to $7 billion in sales of COVID-19 drug through end of 2022